CSCharles W. Schindler

Charles W. Schindler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charles W. Schindler has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Eric B. Thorndike

    NIH/NIDA Preclinical Pharmacology

    8 shared publications
  • Michael H. Baumann

    Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 333 Cassell Drive, Suite 4400, Baltimore, MD 21224, USA

    8 shared publications
  • Kenner C. Rice

    Designer Drug Research Unit (M.R.C., J.S.P., C.W.S., M.H.B.) and Preclinical Pharmacology Section (E.B.T., C.W.S.), National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland; and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism Intramural Research Programs, Rockville, Maryland (K.C.R.)

    4 shared publications
  • Steven R. Goldberg

    Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, National Institute on Drug Abuse, National Institutes of Health, DHHS, Baltimore, MD, USA

    4 shared publications
  • John S. Partilla

    Designer Drug Research Unit (M.R.C., J.S.P., C.W.S., M.H.B.) and Preclinical Pharmacology Section (E.B.T., C.W.S.), National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland; and Drug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism Intramural Research Programs, Rockville, Maryland (K.C.R.)

    3 shared publications
  • Kenner C. Rice

    Department of Health and Human Services,Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Re-search Program, NIDA and the NIAAA, NIH,Bethesda,USA, USA

    3 shared publications

Latest Publications

  • Open Access

    Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials

    by Margaret Haney, Monique Vallée, Sandy Fabre, Stephanie Collins Reed, Marion Zanese, Ghislaine Campistron, Caroline A. Arout, Richard W. Foltin, Ziva D. Cooper, Tonisha Kearney-Ramos, et al.

    Cannabis use disorder (CUD) is widespread, and there is no pharmacotherapy to facilitate its treatment. AEF0117, the first of a new pharmacological class, is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). AEF0117 selectively inhibits a subset of intracellular effects resulting from Δ9-tetrahydrocannabinol (THC) binding without modifying behavior per se. In mice and non-human primates, AEF0117 decreased cannabinoid self-administration and THC-related behavioral impairment without producing significant adverse effects. In single-ascending-dose (0.2 mg, 0.6 mg, 2 mg and 6 mg; n = 40) and multiple-ascending-dose (0.6 mg, 2 mg and 6 mg; n = 24) phase 1 trials, healthy volunteers were randomized to ascending-dose cohorts (n = 8 per cohort; 6:2 AEF0117 to placebo randomization). In both studies, AEF0117 was safe and well tolerated (primary outcome measurements). In a double-blind, placebo-controlled, crossover phase 2a trial, volunteers with CUD were randomized to two ascending-dose cohorts (0.06 mg, n = 14; 1 mg, n = 15). AEF0117 significantly reduced cannabis’ positive subjective effects (primary outcome measurement, assessed by visual analog scales) by 19% (0.06 mg) and 38% (1 mg) compared to placebo (P < 0.04). AEF0117 (1 mg) also reduced cannabis self-administration (P < 0.05). In volunteers with CUD, AEF0117 was well tolerated and did not precipitate cannabis withdrawal. These data suggest that AEF0117 is a safe and potentially efficacious treatment for CUD.ClinicalTrials.gov identifiers: NCT03325595, NCT03443895 and NCT03717272.


  • Open Access

    Physiological effects of fentanyl analogs found in recreational drug markets

    by Charles W. Schindler, Shelby A. McGriff, Eric B. Thorndike, Li Chen, Donna Walther, Kenner Rice, Lei Shi, Michael H. Baumann

    ID 17435 Poster Board 106 Structural analogs of fentanyl are increasingly associated with human overdose fatalities, yet little is known about the pharmacology of these compounds. Here we studied the physiological effects of fentanyl analogs that have appeared in recreational drug markets worldwide. Six male Sprague-Dawley rats received surgically implanted telemetry transmitters for the measurement of blood pressure (BP), heart rate (HR), locomotor activity, and body temperature. Rats in their home cages were placed onto telemetry receivers for 3 h each weekday, with subcutaneous (s.c.) drug or vehicle injections administered twice weekly. We also examined the effects of fentanyl and its analogs in assays measuring opioid receptor binding in rat brain tissue, and inhibition of cAMP accumulation in cells transfected with mu-opioid receptors (MOR). The telemetry results revealed that all fentanyl analogs produce dose-dependent increases in BP, HR, activity, and temperature, but the potency of the compounds varied substantially. The calculated ED50 values for inducing hypertensive effects showed that fentanyl was most potent (0.01 mg/kg), followed closely by furanylfentanyl (0.014 mg/kg), cyclopropylfentanyl (0.028 mg/kg), and butyrylfentanyl (0.081 mg/kg). Acetylfentanyl (0.166 mg/kg) was slightly less potent than butyrylfentanyl, but had a potency similar to the illicit opioid heroin (0.215 mg/kg). Valerylfentanyl was the least potent analog by far (2.071 mg/kg), which had potency similar to the opioid analgesic morphine (2.689 mg/kg). Radioligand binding assays demonstrated that all fentanyl analogs displayed higher affinity for mu-opioid receptors (MOR) over delta and kappa sites, and all of the drugs induced MOR-mediated inhibition of cAMP accumulation. Importantly, the rank order of potency for the fentanyl analogs to increase BP was similar to the rank order of affinity at MOR and potency for inhibiting cAMP. We also tested the ability of opioid receptor antagonists to alter the in vivo effects of fentanyl and butyrylfentanyl. The centrally active opioid antagonist, naltrexone (0.3 mg/kg, s.c.), blocked all of the effects of both drugs, whereas the peripherally restricted opioid antagonist, naloxone methiodide (2.0 mg/kg, s.c.), partially reduced only the BP and HR effects. These findings indicate that locomotor and temperature effects induced by fentanyl and its analogs are centrally mediated, while cardiovascular effects may involve peripheral mechanisms. In conclusion, we demonstrate that fentanyl analogs evoke physiological responses that are similar to fentanyl itself, and these responses are most likely mediated via agonist activity at MOR. With the exception of valerylfentanyl, which is a very low potency agonist, fentanyl analogs are much more potent than morphine, suggesting these analogs may pose serious health risks to users. This work was supported by NIDA/NIH.

  • Neurochemical and Cardiovascular Effects of 4-Chloro Ring-Substituted Synthetic Cathinones in Rats

    by Michael R. Chojnacki, Eric B. Thorndike, John S. Partilla, Kenner C. Rice, Charles W. Schindler, Michael H. Baumann

    Synthetic cathinones are a class of new psychoactive substances that display psychomotor stimulant properties, and novel cathinone analogs continue to emerge in illicit drug markets worldwide. The aim of the present study was to characterize the pharmacology of 4-chloro ring-substituted cathinones that are appearing in illicit drug markets compared with the effects of 4-methylmethcathinone (mephedrone). Synaptosomes were prepared from rat caudate for dopamine transporter (DAT) assays or from whole brain minus caudate and cerebellum for norepinephrine transporter (NET) and serotonin transporter (SERT) assays. Findings from transporter uptake inhibition and release assays showed that mephedrone and 4-chloromethcathinone (4-CMC) function as substrates at DAT, NET, and SERT, with similar potency at all three transporters. In contrast, 4-chloro-α-pyrrolidinopropiophenone (4-CαPPP) was an uptake inhibitor at DAT and NET, with similar potency at each site, but had little activity at SERT. 4-Chloroethcathinone (4-CEC) was a low-potency uptake inhibitor at DAT and NET but a substrate at SERT. In rats implanted with telemetry transmitters, mephedrone and 4-CMC increased blood pressure, heart rate, and locomotor activity to a similar extent. 4-CEC and 4-CαPPP were less potent at increasing blood pressure and had modest stimulatory effects on heart rate and activity. 4-CMC also transiently decreased temperature at the highest dose tested. All three 4-chloro ring-substituted cathinones are biologically active, but only 4-CMC has potency comparable to mephedrone. Collectively, our findings suggest that 4-CMC and other 4-chloro cathinones may have abuse potential and adverse effects in humans that are analogous to those associated with mephedrone. SIGNIFICANCE STATEMENT The 4-chloro ring-substituted cathinones all produced significant cardiovascular stimulation, with 4-chloromethcathinone (4-CMC) showing potency similar to mephedrone. All of the drugs are likely to be abused given their effects at the dopamine transporter, particularly 4-CMC.


  • Reinforcing effects of phenethylamine analogs found in dietary supplements

    by Shelby A. McGriff, Michael R. Chojnacki, Eric B. Thorndike, Kenner C. Rice, Michael H. Baumann, Charles W. Schindler

    Rationale Synthetic phenethylamine (PEA) analogs, such as β-methylphenethylamine (BMPEA) and N,α-diethylphenethylamine (DEPEA), are often found in dietary supplements, despite regulations prohibiting their sale. PEA analogs are structurally related to amphetamine, and we have shown that BMPEA and DEPEA produce cardiovascular stimulation mimicking the effects of amphetamine. However, few studies have examined behavioral effects of BMPEA, DEPEA, and other PEA analogs. Objectives Here, we examined the reinforcing effects of α-ethylphenethylamine (AEPEA, 1 mg/kg/injection), DEPEA (1 mg/kg/injection), and BMPEA (3 mg/kg/injection) as compared to amphetamine (0.1 mg/kg/injection) using a fixed-ratio 1 self-administration paradigm in male rats. Methods Male rats were trained in self-administration chambers containing 2 nose-poke holes. A nose-poke response in the active hole delivered drug or saline, whereas a nose-poke response in the inactive hole had no programmed consequence. Four groups of rats were initially trained for 10 days with the doses noted above. Upon acquisition of drug self-administration, a dose–effect function was determined by training rats on 3 additional doses for 3 days each. A separate group of rats was trained with saline. Results Male rats self-administered each PEA analog and amphetamine, as shown by significant increases in active responses versus inactive responses. Subsequent dose–response testing showed clear differences in potency of the compounds. Amphetamine showed a typical inverted U-shaped dose–effect function, peaking at 0.1 mg/kg/injection. AEPEA and DEPEA also showed inverted dose–effect functions, with each peaking at 0.3 mg/kg/injection. BMPEA did not show an inverted U-shaped dose–effect function, but active responding slowly increased up to a dose of 6 mg/kg/injection. Conclusions Taken together, our findings indicate that dietary supplements containing PEA analogs may have significant abuse liability when used recreationally.


  • Open Access

    Reinforcing Effects of Phenethylamine Analogs Found in Dietary Supplements

    by Shelby McGriff, Eric Thorndike, Kenner Rice, Michael Baumann, Charles Schindler

    HYPOTHESIS: Phenethylamine analogs are often found in dietary supplements, even though they are rarely listed on the ingredient label. Due to their structural similarities to amphetamine, it is anticipated that these compounds display comparable pharmacological effects to amphetamine and other stimulants. Here, we compared the effects of amphetamine and selected phenethylamine analogs on drug self‐administration behavior in rats. METHODS: Male Sprague‐Dawley rats fitted with intravenous (i.v.) jugular catheters were placed in experimental chambers containing two nose poke holes. Active nose poke responses resulted in delivery of a constant volume of drug (0.2 mL) over a period of 2 s on a fixed‐ratio 1 schedule, followed by a 20 s timeout. Acquisition doses for the compounds were 0.1 mg/kg/inj amphetamine, 1 mg/kg/inj a‐ethylphenethylamine (AEPEA) and N,a‐diethylphenethylamine (DEPEA), and 3 mg/kg/inj b‐methylphenethylamine (BMPEA). Following 10 days of acquisition training, dose‐effect testing began with three additional doses, each of which were tested for 3 days. Subjects then returned to the original training dose until responses stabilized. RESULTS: At the end of acquisition training, all four compounds showed a significant difference in active versus inactive nose pokes (p<0.0001), indicating that subjects acquired drug self‐administration. During dose‐effect testing, all the drugs showed a typical inverted dose‐effect function, although there were clear differences in potency. Maximum responding was maintained at 0.03 mg/kg/inj for amphetamine, 0.3 mg/kg/inj for DEPEA and AEPEA and over 1 mg/kg/inj for BMPEA. AEPEA and DEPEA appeared to maintain higher rates of responding than amphetamine, potentially reflecting differences in duration of action. Self‐administration of BMPEA occurred despite BMPEA showing minimal locomotor stimulating effects in a previous experiment. CONCLUSION: Direct comparisons between the three phenethylamine analogs and amphetamine show that these compounds support self‐administration, indicating that dietary supplements containing these compounds could have significant abuse liability.

  • Amphetamine-like Neurochemical and Cardiovascular Effects of α-Ethylphenethylamine Analogs Found in Dietary Supplements

    by Charles W. Schindler, Eric B. Thorndike, John S. Partilla, Kenner C. Rice, Michael H. Baumann

    Dietary supplements often contain additives not listed on the label, including α-ethyl homologs of amphetamine such as N,α-diethylphenethylamine (DEPEA). Here, we examined the neurochemical and cardiovascular effects of α-ethylphenethylamine (AEPEA), N-methyl-α-ethylphenethylamine (MEPEA), and DEPEA as compared with the effects of amphetamine. All drugs were tested in vitro using uptake inhibition and release assays for monoamine transporters. As expected, amphetamine acted as a potent and efficacious releasing agent at dopamine transporters (DAT) and norepinephrine transporters (NET) in vitro. AEPEA and MEPEA were also releasers at catecholamine transporters, with greater potency at NET than DAT. DEPEA displayed fully efficacious release at NET but weak partial release at DAT (i.e., 40% of maximal effect). In freely moving, conscious male rats fitted with biotelemetry transmitters for physiologic monitoring, amphetamine (0.1–3.0 mg/kg, s.c.) produced robust dose-related increases in blood pressure (BP), heart rate (HR), and motor activity. AEPEA (1–10 mg/kg, s.c.) produced significant increases in BP but not HR or activity, whereas DEPEA and MEPEA (1–10 mg/kg, s.c.) increased BP, HR, and activity. In general, the phenethylamine analogs were approximately 10-fold less potent than amphetamine. Our results show that α-ethylphenethylamine analogs are biologically active. Although less potent than amphetamine, they produce cardiovascular effects that could pose risks to humans. Given that MEPEA and DEPEA increased locomotor activity, these substances may also have significant abuse potential. SIGNIFICANCE STATEMENT The α-ethyl homologs of amphetamine have significant cardiovascular, behavioral, and neurochemical effects in rats. Given that these compounds are often not listed on the ingredient labels of dietary supplements, these compounds could pose a risk to humans using these products.


  • Open Access

    Stereoselective neurochemical, behavioral, and cardiovascular effects of α‐pyrrolidinovalerophenone enantiomers in male rats

    by Charles W. Schindler, Eric B. Thorndike, Hailey M. Walters, Donna Walther, Kenner C. Rice, Michael H. Baumann

    The synthetic cathinone α‐pyrrolidinovalerophenone (α‐PVP) continues to be abused despite being banned by regulatory agencies. The abused formulation of α‐PVP is a racemic mixture consisting of two enantiomers, S‐α‐PVP and R‐α‐PVP. In this study, we investigated the neurochemical, behavioral, and cardiovascular effects of racemic α‐PVP and its enantiomers in male rats. Racemic α‐PVP blocked the uptake of both dopamine and norepinephrine ex vivo, but did not block the uptake of serotonin (5‐HT), at their respective transporters. S‐α‐PVP was slightly more potent than racemic α‐PVP, while R‐α‐PVP was 10 to 20 times less potent at blocking dopamine and norepinephrine uptake. In microdialysis studies, racemic and S‐α‐PVP increased extracellular dopamine levels in the nucleus accumbens, but not levels of 5‐HT. Racemic and S‐α‐PVP also increased locomotor activity. When tested at the same doses, S‐α‐PVP produced larger effects than racemic α‐PVP. R‐α‐PVP also increased extracellular dopamine levels and locomotor activity, but only at 30 times higher doses than S‐α‐PVP. Racemic and S‐α‐PVP were self‐administered by rats at 0.03 mg/kg/injection, whereas R‐α‐PVP was self‐administered at a 10 times higher dose. Dose‐effect determinations following acquisition suggested that R‐α‐PVP was at least 30 times less potent than S‐α‐PVP. Finally, racemic and S‐α‐PVP increased blood pressure and heart rate at doses approximately 30 times less than was required for R‐α‐PVP to produce similar effects. These results show that the neurochemical, behavioral, and cardiovascular effects of racemic α‐PVP most likely reflect the actions of S isomer.


  • The Supplement Adulterant β-Methylphenethylamine Increases Blood Pressure by Acting at Peripheral Norepinephrine Transporters

    by Charles W. Schindler, Eric B. Thorndike, Kenner C. Rice, John S. Partilla, Michael H. Baumann

    β-Methylphenethylamine [(BMPEA), 2-phenylpropan-1-amine] is a structural isomer of amphetamine (1-phenylpropan-2-amine) that has been identified in preworkout and weight loss supplements, yet little information is available about its pharmacology. Here, the neurochemical and cardiovascular effects of BMPEA and its analogs, N-methyl-2-phenylpropan-1-amine (MPPA) and N,N-dimethyl-2-phenylpropan-1-amine (DMPPA), were compared with structurally related amphetamines. As expected, amphetamine and methamphetamine were potent substrate-type releasing agents at dopamine transporters (DATs) and norepinephrine transporters (NETs) in rat brain synaptosomes. BMPEA and MPPA were also substrates at DATs and NETs, but they were at least 10-fold less potent than amphetamine. DMPPA was a weak substrate only at NETs. Importantly, the releasing actions of BMPEA and MPPA were more potent at NETs than DATs. Amphetamine produced significant dose-related increases in blood pressure (BP), heart rate (HR), and locomotor activity in conscious rats fitted with surgically implanted biotelemetry transmitters. BMPEA, MPPA, and DMPPA produced increases in BP that were similar to the effects of amphetamine, but the compounds failed to substantially affect HR or activity. The hypertensive effect of BMPEA was reversed by the α-adrenergic antagonist prazosin but not the ganglionic blocker chlorisondamine. Radioligand binding at various G protein–coupled receptors did not identify nontransporter sites of action that could account for cardiovascular effects of BMPEA or its analogs. Our results show that BMPEA, MPPA, and DMPPA are biologically active. The compounds are unlikely to be abused due to weak effects at DATs, but they could produce adverse cardiovascular effects via substrate activity at peripheral NET sites.


  • Synthetic cannabinoids found in “spice” products alter body temperature and cardiovascular parameters in conscious male rats

    by Charles W. Schindler, Benjamin R. Gramling, Zuzana Justinova, Eric B. Thorndike, Michael H. Baumann


  • Open Access

    Pharmacological mechanisms underlying the cardiovascular effects of the “bath salt” constituent 3,4‐methylenedioxypyrovalerone (MDPV)

    by Charles W Schindler, Eric B Thorndike, Masaki Suzuki, Kenner C Rice, Michael H Baumann

    Background and Purpose: 3,4‐Methylenedioxypyrovalerone (MDPV) is a synthetic cathinone with stimulatory cardiovascular effects that can lead to serious medical complications. Here, we examined the pharmacological mechanisms underlying these cardiovascular actions of MDPV in conscious rats.Experimental Approach: Male Sprague–Dawley rats had telemetry transmitters surgically implanted for the measurement of BP and heart rate (HR). On test days, rats were placed individually in standard isolation cubicles. Following drug treatment, cardiovascular parameters were monitored for 3 h sessions.Key Results: Racemic MDPV (0.3–3.0 mg·kg−1) increased BP and HR in a dose‐dependent manner. The S(+) enantiomer (0.3–3.0 mg·kg−1) of MDPV produced similar effects, while the R(−) enantiomer (0.3–3.0 mg·kg−1) had no effects. Neither of the hydroxylated phase I metabolites of MDPV altered cardiovascular parameters significantly from baseline. Pretreatment with the ganglionic blocker chlorisondamine (1 and 3 mg·kg−1) antagonized the increases in BP and HR produced by 1 mg·kg−1MDPV. The α1‐adrenoceptor antagonist prazosin (0.3 mg·kg−1) attenuated the increase in BP following MDPV, while the β‐adrenoceptor antagonists propranolol (1 mg·kg−1) and atenolol (1 and 3 mg·kg−1) attenuated the HR increases.Conclusions and Implications: The S(+) enantiomer appeared to mediate the cardiovascular effects of MDPV, while the metabolites of MDPV did not alter BP or HR significantly; MDPV increased BP and HR through activation of central sympathetic outflow. Mixed‐action α/β‐adrenoceptor antagonists may be useful as treatments in counteracting the adverse cardiovascular effects of MDPV.